Suven Life Scie.

Why is Suven Life Sciences Ltd falling/rising?

As of 30-Aug, Suven Life Sciences Ltd's stock price is at 364.90, down 2.8 (-0.76%), and has underperformed its sector. The company faces significant financial challenges, including operating losses and declining sales, which have contributed to the recent stock decline despite strong long-term performance.

As of 30-Aug, Suven Life Sciences Ltd's stock price is falling, currently at 364.90, reflecting a decrease of 2.8 (-0.76%). The stock has underperformed its sector by 1.62% today and has been on a consecutive decline for the last two days, with a total drop of 2.04% in that period. This decline is compounded by a significant reduction in investor participation, as evidenced by a delivery volume of 1.22 lacs on 27 August, which has fallen by 78.08% compared to the 5-day average.<BR><BR>Despite a strong performance over the longer term, with a 118.70% increase year-to-date and a 457.87% rise over the last three years, the company's current fundamentals are concerning. The company has reported operating losses, with net sales declining at an annual rate of 8.90% and an alarming operating profit decrease of 205.51% over the past five years. Additionally, the company has a negative EBITDA of Rs. -366.25 cr and a poor EBIT to Interest ratio of -189.29, indicating weak financial health and an inability to service its debt effectively.<BR><BR>The recent quarterly results have also been disappointing, with a profit after tax of Rs -127.61 cr, which represents a decline of 84.7% compared to the previous four-quarter average. The lowest debtor turnover ratio at 4.72 times further highlights the company's struggles. These factors contribute to the stock's current downward trend, despite its historical performance.

Which are the latest news on Suven Life Scie.?

Who are in the management team of Suven Life Scie.?

The management team of Suven Life Sciences includes Venkateswarlu Jasti (Chairman & CEO), Sudha Rani Jasti (Whole-time Director), Seyed E Hasnain (Director), and several Independent Directors: M Gopalakrishna, Santanu Mukherjee, and J A S Padmaja, along with Shrenik Soni as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Suven Life Sciences includes the following individuals:<BR><BR>1. **Venkateswarlu Jasti** - Chairman & CEO<BR>2. **Sudha Rani Jasti** - Whole-time Director<BR>3. **Seyed E Hasnain** - Director<BR>4. **M Gopalakrishna** - Independent Director<BR>5. **Santanu Mukherjee** - Independent Director<BR>6. **J A S Padmaja** - Independent Director<BR>7. **Shrenik Soni** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Suven Life Scie. do?

Suven Life Sciences Ltd is a small-cap healthcare services company, incorporated in 1989, with recent quarterly net sales of 4 Cr and a net loss of 128 Cr as of June 2026. The company has a market cap of INR 9,446 Cr and operates under a negative return on equity of -46.73%.

Overview:<BR>Suven Life Sciences Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated in March 1989 and changed its name from Suven Pharmaceuticals Ltd to Suven Life Sciences Ltd in September 2003. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -128 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 9,446 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.85 <BR>Return on Equity: -46.73% <BR>Price to Book: 15.69<BR><BR>Contact Details:<BR>Address: #8-2-334 SDE Serene Chambers, 6 th Floor Road No 5 Avenue 7 Hyderabad Telangana : 500034 <BR>Tel: 91-40-23541142/3311/3315 <BR>Email: info@suven.com <BR>Website: http://www.suven.com

Who are the peers of the Suven Life Scie.?

Peers of Suven Life Sciences include Syngene International, Vijaya Diagnostics, Indegene, Metropolis Healthcare, Thyrocare Technologies, Vimta Labs, Krsnaa Diagnostics, Tarsons Products, and Suraksha Diagnostics. Most peers show Below Average growth and capital structure, with Vijaya Diagnostics having the highest 1-year return at 40.55%, while Suven Life Sciences has a 1-year return of 41.42%.

Peers: The peers of Suven Life Scie. are Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., Tarsons Products, and Suraksha Diagno.<BR><BR>Quality Snapshot: Excellent management risk is observed at Syngene Intl., Vijaya Diagnost., Thyrocare Tech., and Suraksha Diagno., while Average management risk is found at Indegene, Metropolis Healt, Vimta Labs, and Krsnaa Diagnost., and the rest have Below Average management risk. All peers exhibit Below Average growth except for Suraksha Diagno. which has Good growth, while the rest, including Syngene Intl., Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., and Tarsons Products, show Below Average growth. Excellent capital structure is noted for Syngene Intl., Vijaya Diagnost., Indegene, Vimta Labs, and Krsnaa Diagnost., while Good capital structure is seen at Metropolis Healt, and the rest, including Suven Life Scie. and Tarsons Products, have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vijaya Diagnost. at 40.55%, while the lowest is Syngene Intl. at -39.04%. Suven Life Scie. has a 1-year return of 41.42%, which is higher than Syngene Intl. but lower than Vijaya Diagnost. Additionally, Krsnaa Diagnost. and Syngene Intl. have negative six-month returns.

How big is Suven Life Scie.?

As of 14th August, Suven Life Sciences Ltd has a market capitalization of 9,662.23 Cr, with recent net sales of 8.82 Cr and a net loss of 352.44 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Suven Life Sciences Ltd has a market capitalization of 9,662.23 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8.82 Cr, while the sum of Net Profit for the same period reflects a loss of 352.44 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2026. Shareholder's Funds are valued at 591.40 Cr, and Total Assets amount to 624.21 Cr.

Should I buy, sell or hold Suven Life Sciences Ltd?

When is the next results date for Suven Life Sciences Ltd?

The next results date for Suven Life Sciences Ltd is August 6, 2026.

The next results date for Suven Life Sciences Ltd is scheduled for August 6, 2026.

Are Suven Life Sciences Ltd latest results good or bad?

Suven Life Sciences Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹45.60 crores, a 55.26% increase in losses, and a 45.91% drop in revenue. The negative operating margin and return on equity indicate significant operational challenges, leading to a 2.53% decline in stock price, suggesting caution for investors.

Suven Life Sciences Ltd's latest results for Q4 FY26 indicate a challenging financial situation. The company reported a net loss of ₹45.60 crores, which is a significant increase of 55.26% in losses compared to the previous quarter. Revenue also saw a sharp decline, dropping 45.91% from ₹2.81 crores in Q3 FY26 to just ₹1.52 crores in Q4 FY26. <BR><BR>The operating margin is alarmingly negative at -3,331.58%, highlighting severe operational distress. Additionally, the return on equity stands at -75.33%, reflecting ongoing capital inefficiency. <BR><BR>Overall, these results suggest that Suven Life Sciences is facing substantial operational challenges, and the market's reaction, with a 2.53% decline in stock price following the announcement, underscores growing skepticism about the company's ability to turn around its fortunes. Investors should approach this situation with caution, as the company has yet to demonstrate a clear path to profitability amidst these persistent losses.

Is Suven Life Scie. technically bullish or bearish?

As of December 3, 2025, the technical trend has shifted to mildly bearish, indicated by bearish signals from the weekly MACD and KST, daily moving averages, and Bollinger Bands, despite a bullish weekly RSI and strong year-to-date performance.

As of 3 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages confirm a bearish outlook. The weekly RSI remains bullish, but the overall technical indicators suggest a weakening trend. The Bollinger Bands show a mildly bearish signal on the weekly timeframe, further supporting the bearish stance. Despite a strong performance year-to-date and over longer periods, the recent trend shift indicates caution in the near term.

How has been the historical performance of Suven Life Scie.?

Suven Life Sciences has experienced a significant decline in financial performance, with net sales dropping from 285.67 crore in March 2019 to 6.66 crore in March 2025, and increasing losses leading to a net profit of -160.75 crore in March 2025. The company faces ongoing operational challenges, reflected in negative cash flow and reduced asset values.

Answer:<BR>The historical performance of Suven Life Sciences has shown a significant decline in key financial metrics over the years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Suven Life Sciences reported net sales of 6.66 crore in March 2025, a sharp decrease from 11.69 crore in March 2024 and 13.54 crore in March 2023, continuing a downward trend from 285.67 crore in March 2019. The total operating income mirrored this decline, dropping to 6.66 crore in March 2025 from 11.69 crore in the previous year. The company's total expenditure, excluding depreciation, rose to 172.43 crore in March 2025, up from 139.70 crore in March 2024, leading to an operating profit (PBDIT) of -165.77 crore in March 2025, worsening from -128.01 crore in March 2024. Consequently, the profit before tax also deteriorated to -160.75 crore in March 2025, compared to -106.08 crore in March 2024. The net profit for March 2025 was reported at -160.75 crore, a decline from -105.08 crore in March 2024. The company's total assets decreased to 135.18 crore in March 2025 from 284.90 crore in March 2024, while total liabilities also fell to 135.18 crore from 284.90 crore in the same period. Cash flow from operating activities remained negative at -154.00 crore in March 2025, indicating ongoing operational challenges. Overall, Suven Life Sciences has faced significant financial difficulties, reflected in declining sales, increasing losses, and reduced asset values over the years.

Is Suven Life Scie. overvalued or undervalued?

As of October 14, 2020, Suven Life Sciences is considered overvalued and risky due to negative financial ratios, including a PE ratio of -30.02 and an EV to EBITDA of -28.75, despite a strong historical return of 128.61% over the past year.

As of 14 October 2020, the valuation grade for Suven Life Sciences moved from expensive to risky. The company is currently considered overvalued based on its financial ratios, which include a PE ratio of -30.02, an EV to EBITDA of -28.75, and a ROCE of -343.32%. These figures indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Suven Life Sciences stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight that Suven Life Sciences is not only underperforming but also carries a much higher risk profile. Despite a strong historical performance with a 1Y return of 128.61% compared to the Sensex's 7.61%, the current valuation metrics suggest that the stock is overvalued and may not be a prudent investment at this time.

Who are the top shareholders of the Suven Life Scie.?

The top shareholders of Suven Life Sciences include Jasti Property And Equity Holdings Private Limited with 69.56%, individual investors with 24.04%, and foreign institutional investors holding 0.25%. There are no pledged promoter holdings or significant public shareholders.

The top shareholders of Suven Life Sciences primarily include the promoters, with Jasti Property And Equity Holdings Private Limited being the largest shareholder, holding 69.56% of the company. There are also individual investors who collectively own 24.04% of the shares. Additionally, mutual funds hold a very small percentage (0.01%) across three schemes, and foreign institutional investors (FIIs) have a combined holding of 0.25% through 14 different entities. There are no pledged promoter holdings or significant public shareholders noted.

What is the bonus history of the Suven Life Scie.?

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue announced on March 23, 2007, with a record date of April 2, 2007, allowing shareholders to receive an additional share for each share held.

Suven Life Sciences Ltd has a bonus history that includes a 1:1 bonus issue. This was announced with an ex-date of March 23, 2007, and the record date for this bonus was April 2, 2007. This means that shareholders on record as of the record date received an additional share for every share they held.

Has Suven Life Scie. declared dividend?

Yes, Suven Life Sciences Ltd has declared a dividend of 150% (₹1.5 per share) with an ex-date of February 14, 2019. However, the dividend yield is 0%, indicating that returns are mainly from price appreciation rather than dividend income.

Suven Life Sciences Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 1.5<BR>- Ex-date: 14 Feb 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 47.35%, the dividend return was 0%, resulting in a total return of 47.35%.<BR><BR>For the 1-year period, the price return was 135.02%, the dividend return was 0%, leading to a total return of 135.02%.<BR><BR>Over the 2-year period, the price return was 267.93%, with a dividend return of 0%, culminating in a total return of 267.93%.<BR><BR>In the 3-year period, the price return was 176.98%, the dividend return was 0%, which resulted in a total return of 176.98%.<BR><BR>For the 4-year period, the price return was 133.95%, the dividend return was 0%, giving a total return of 133.95%.<BR><BR>In the 5-year period, the price return was 516.17%, with a dividend return of 0%, resulting in a total return of 516.17%.<BR><BR>Overall, while Suven Life Sciences Ltd has declared a significant dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The total returns over various periods show strong performance, particularly over the longer term.